IL94330A - A pharmaceutical preparation containing a hormone that releases gonadotropin - Google Patents
A pharmaceutical preparation containing a hormone that releases gonadotropinInfo
- Publication number
- IL94330A IL94330A IL9433090A IL9433090A IL94330A IL 94330 A IL94330 A IL 94330A IL 9433090 A IL9433090 A IL 9433090A IL 9433090 A IL9433090 A IL 9433090A IL 94330 A IL94330 A IL 94330A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- disease
- symptoms
- Prior art date
Links
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 title claims abstract description 22
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 title claims description 30
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 title claims description 21
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 title claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 67
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 230000004899 motility Effects 0.000 claims abstract description 18
- 208000035475 disorder Diseases 0.000 claims description 25
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 206010010774 Constipation Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 206010039710 Scleroderma Diseases 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 8
- 206010061296 Motor dysfunction Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 206010060811 Hollow visceral myopathy Diseases 0.000 claims description 5
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 54
- 238000011282 treatment Methods 0.000 abstract description 53
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
- 108010000817 Leuprolide Proteins 0.000 description 55
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 50
- 229960004338 leuprorelin Drugs 0.000 description 50
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 26
- 238000002560 therapeutic procedure Methods 0.000 description 24
- 206010028813 Nausea Diseases 0.000 description 22
- 230000008693 nausea Effects 0.000 description 22
- 208000004998 Abdominal Pain Diseases 0.000 description 19
- 206010047700 Vomiting Diseases 0.000 description 17
- 230000008673 vomiting Effects 0.000 description 16
- 102000009151 Luteinizing Hormone Human genes 0.000 description 13
- 108010073521 Luteinizing Hormone Proteins 0.000 description 13
- 229940040129 luteinizing hormone Drugs 0.000 description 13
- 229960003387 progesterone Drugs 0.000 description 13
- 239000000186 progesterone Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000002496 gastric effect Effects 0.000 description 10
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 9
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 210000001015 abdomen Anatomy 0.000 description 8
- 229940028334 follicle stimulating hormone Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000008574 D-amino acids Chemical group 0.000 description 7
- 210000003403 autonomic nervous system Anatomy 0.000 description 7
- 230000016087 ovulation Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 229930182833 estradiol Natural products 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 206010000087 Abdominal pain upper Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 5
- 229940087857 lupron Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000006771 Gonadotropins Human genes 0.000 description 4
- 108010086677 Gonadotropins Proteins 0.000 description 4
- 239000002622 gonadotropin Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010053240 Glycogen storage disease type VI Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
- 230000003888 Roux-en-Y anastomosis Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000009809 bilateral salpingo-oophorectomy Methods 0.000 description 3
- 238000002192 cholecystectomy Methods 0.000 description 3
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940080861 demerol Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960001253 domperidone Drugs 0.000 description 3
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 3
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical group O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000019430 Motor disease Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010057969 Reflux gastritis Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 238000012820 exploratory laparotomy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000960 hypophysis hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- RRHJHSBDJDZUGL-UHFFFAOYSA-N lidamidine Chemical compound CN=C(N)NC(=O)NC1=C(C)C=CC=C1C RRHJHSBDJDZUGL-UHFFFAOYSA-N 0.000 description 2
- 229960005045 lidamidine Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 210000003903 pelvic floor Anatomy 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000011539 total abdominal hysterectomy Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- VVBDLEHCIKUJSA-XLIKFSOKSA-N (2s)-2-[[(2s)-3-hydroxy-2-[[(2s)-2-[[(2s)-3-(1h-imidazol-5-yl)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 VVBDLEHCIKUJSA-XLIKFSOKSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 description 1
- 206010012205 Delayed puberty Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 206010017753 Gastric atony Diseases 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 101100205180 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-6 gene Proteins 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 238000011538 abdominal hysterectomy Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229960005064 buserelin acetate Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000037020 contractile activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000001096 cystic duct Anatomy 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000000991 decompressive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 210000001619 diaphragma pelvis Anatomy 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003844 drug implant Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000002181 esophagogastroduodenoscopy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000019016 inability to swallow Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000005664 megacystis-microcolon-intestinal hypoperistalsis syndrome Diseases 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003249 myenteric plexus Anatomy 0.000 description 1
- 230000003183 myoelectrical effect Effects 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960004309 nafarelin acetate Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000008904 neural response Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000000136 postovulatory effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- -1 relaxins Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 210000004514 sphincter of oddi Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 208000019183 visceral myopathy Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/349,717 US5068221A (en) | 1989-05-09 | 1989-05-09 | Treatment of motility disorders with a gnrh analog |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL94330A0 IL94330A0 (en) | 1991-03-10 |
| IL94330A true IL94330A (en) | 1995-03-30 |
Family
ID=23373648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9433090A IL94330A (en) | 1989-05-09 | 1990-05-08 | A pharmaceutical preparation containing a hormone that releases gonadotropin |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5068221A (de) |
| EP (1) | EP0471761B1 (de) |
| JP (1) | JPH04505016A (de) |
| KR (1) | KR920700676A (de) |
| AT (1) | ATE110277T1 (de) |
| AU (2) | AU628763B2 (de) |
| CA (1) | CA2053880C (de) |
| DE (1) | DE69011857T2 (de) |
| DK (1) | DK0471761T3 (de) |
| ES (1) | ES2057565T3 (de) |
| IL (1) | IL94330A (de) |
| NZ (1) | NZ248242A (de) |
| WO (1) | WO1990013308A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434136A (en) * | 1990-12-14 | 1995-07-18 | Mathias; John R. | Treatment of motility disorders with a GNRH analog |
| US5470847A (en) * | 1993-12-10 | 1995-11-28 | Board Of Regents, The University Of Texas System | Ovulation control by regulating nitric oxide levels with arginine derivatives |
| KR100440643B1 (ko) * | 1999-01-28 | 2004-07-21 | 쥬가이 세이야쿠 가부시키가이샤 | 치환 페네틸아민 유도체 |
| CA2522690A1 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
| US20200146313A1 (en) * | 2018-11-09 | 2020-05-14 | Ims Trading, Llc | Edible pet chews and methods of forming the same |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO139560C (no) * | 1972-04-29 | 1979-04-04 | Takeda Chemical Industries Ltd | Analogifremgangsmaate til fremstilling av terapeutisk virksomme nonapeptidamid-derivater |
| CA1009230A (en) * | 1972-09-26 | 1977-04-26 | Daiichi Seiyaku Co. | Peptides effecting to the release of sex hormones and a method for preparing the same |
| JPS563846B2 (de) * | 1972-10-12 | 1981-01-27 | ||
| AT347054B (de) * | 1973-09-29 | 1978-12-11 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von neuen nonapeptidamid-derivaten |
| US3914412A (en) * | 1973-10-11 | 1975-10-21 | Abbott Lab | {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity |
| US4005063A (en) * | 1973-10-11 | 1977-01-25 | Abbott Laboratories | [Des-gly]10 -GnRH nonapeptide anide analogs in position 6 having ovulation-inducing activity |
| US4072668A (en) * | 1973-11-06 | 1978-02-07 | The Salk Institute For Biological Studies | LH-RH Analogs |
| US4552764A (en) * | 1974-11-14 | 1985-11-12 | Research Corporation | Peptides for control of intestinal motility |
| US4010261A (en) * | 1974-11-25 | 1977-03-01 | Abbott Laboratories | Method to prevent reproduction with [Des-Gly]10 -GN-RH nonadeptide amide analogs in position |
| US4002738A (en) * | 1975-05-30 | 1977-01-11 | Abbott Laboratories | Treatment of specified neoplasias |
| US4005194A (en) * | 1975-06-23 | 1977-01-25 | Abbott Laboratories | Treatment of prostatic hyperplasia |
| US4018914A (en) * | 1975-11-13 | 1977-04-19 | Abbott Laboratories | Parturition inducement |
| JPS54148722A (en) * | 1978-05-12 | 1979-11-21 | Takeda Chem Ind Ltd | Nonapeptide and its preparation |
| FR2465486A1 (fr) * | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| US4409208A (en) * | 1980-04-15 | 1983-10-11 | The Salk Institute For Biological Studies | GnRH antagonists |
| US4410514A (en) * | 1982-12-06 | 1983-10-18 | The Salk Institute For Biological Studies | GnRH Agonists |
| US4619914A (en) * | 1983-03-10 | 1986-10-28 | The Salk Institute For Biological Studies | GNRH antagonists IIIB |
| US4569927A (en) * | 1984-02-23 | 1986-02-11 | The Salk Institute For Biological Studies | GnRH Antagonists IV |
| US4652550A (en) * | 1984-05-21 | 1987-03-24 | The Salk Institute For Biological Studies | GnRH antagonists VII |
| US4565804A (en) * | 1984-09-07 | 1986-01-21 | The Salk Institute For Biological Studies | GnRH Antagonists VI |
| US4752577A (en) * | 1984-09-13 | 1988-06-21 | Eli Lilly And Company | Method for using a novel transcriptional- and translational-activating sequence in streptomyces |
| US4690916A (en) * | 1984-11-13 | 1987-09-01 | Syntex (U.S.A.) Inc. | Nona and decapeptide analogs of LHRH useful as LHRH antagonists |
| US4740500A (en) * | 1985-01-31 | 1988-04-26 | The Salk Institute For Biological Studies | GnRH antagonists VIII |
| US4725577A (en) * | 1985-04-25 | 1988-02-16 | Administrators Of The Tulane Educational Fund | Biologically active lysine containing octapeptides |
| US4661472A (en) * | 1985-05-09 | 1987-04-28 | The Salk Institute For Biological Studies | GnRH antagonists IX |
| US4920102A (en) * | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
-
1989
- 1989-05-09 US US07/349,717 patent/US5068221A/en not_active Expired - Lifetime
-
1990
- 1990-05-03 KR KR1019910701549A patent/KR920700676A/ko not_active Abandoned
- 1990-05-03 DE DE69011857T patent/DE69011857T2/de not_active Expired - Fee Related
- 1990-05-03 CA CA002053880A patent/CA2053880C/en not_active Expired - Fee Related
- 1990-05-03 DK DK90907817.2T patent/DK0471761T3/da active
- 1990-05-03 JP JP2507135A patent/JPH04505016A/ja active Pending
- 1990-05-03 WO PCT/US1990/002455 patent/WO1990013308A1/en not_active Ceased
- 1990-05-03 ES ES90907817T patent/ES2057565T3/es not_active Expired - Lifetime
- 1990-05-03 AT AT90907817T patent/ATE110277T1/de not_active IP Right Cessation
- 1990-05-03 EP EP90907817A patent/EP0471761B1/de not_active Expired - Lifetime
- 1990-05-03 AU AU55595/90A patent/AU628763B2/en not_active Ceased
- 1990-05-07 NZ NZ248242A patent/NZ248242A/en unknown
- 1990-05-08 IL IL9433090A patent/IL94330A/en not_active IP Right Cessation
-
1992
- 1992-05-12 AU AU16203/92A patent/AU639403B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK0471761T3 (da) | 1994-09-19 |
| ES2057565T3 (es) | 1994-10-16 |
| KR920700676A (ko) | 1992-08-10 |
| EP0471761B1 (de) | 1994-08-24 |
| CA2053880C (en) | 1997-01-14 |
| AU639403B2 (en) | 1993-07-22 |
| NZ248242A (en) | 1997-07-27 |
| AU628763B2 (en) | 1992-09-17 |
| IL94330A0 (en) | 1991-03-10 |
| EP0471761A1 (de) | 1992-02-26 |
| JPH04505016A (ja) | 1992-09-03 |
| US5068221A (en) | 1991-11-26 |
| CA2053880A1 (en) | 1990-11-10 |
| WO1990013308A1 (en) | 1990-11-15 |
| DE69011857T2 (de) | 1995-03-23 |
| AU1620392A (en) | 1992-07-30 |
| ATE110277T1 (de) | 1994-09-15 |
| DE69011857D1 (de) | 1994-09-29 |
| EP0471761A4 (en) | 1992-06-24 |
| AU5559590A (en) | 1990-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5434136A (en) | Treatment of motility disorders with a GNRH analog | |
| Mathias et al. | Effect of leuprolide acetate in patients with moderate to severe functional bowel disease: Double-blind, placebo-controlled study | |
| Felberbaum et al. | Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. | |
| EP4094766B1 (de) | Orale festdosiskombination und ihre verwendung bei der behandlung von uterusmyomien und endometriose | |
| RU2110274C1 (ru) | Способ лечения состояния, зависящего от эстрогенов яичников | |
| EP0612531B1 (de) | Therapeutischer Wirkstoff für Erkrankungen des Verdauungstraktes | |
| Kellow et al. | Sensitivities of human jejunum, ileum, proximal colon, and gallbladder to cholecystokinin octapeptide | |
| Mathias et al. | Debilitating “functional” bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog | |
| Van der Sijp et al. | Circulating gastrointestinal hormone abnormalities in patients with severe idiopathic constipation | |
| US10858388B2 (en) | Selective progesterone receptor modulator (SPRM) regimen | |
| CA2053880C (en) | Treatment of motility disorders with a gnrh analog | |
| US7727959B2 (en) | Use of substances with oxytocin activity against climacteric disorders | |
| Lombardi et al. | CV 205-502 treatment in therapy-resistant acromegalic patients | |
| JPH04230223A (ja) | ソマトスタチン吸収改善医薬組成物、その製法および用途 | |
| RU2181598C2 (ru) | Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения | |
| US5166192A (en) | Treatment of motility disorders with a GnRH analog | |
| US20040176284A1 (en) | Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis | |
| BR112020021565A2 (pt) | Composição para tratamento de uma ou mais doenças relacionadas com estrogênio | |
| Buchin | Swallowing disorders: diagnosis and medical treatment | |
| WO2008121046A1 (en) | Improvement of gastric emptying in patients suffering from diabetes mellitus | |
| JPH11228403A (ja) | 消化管運動機能改善剤 | |
| CA2117843A1 (en) | Agent for suppressing the motor activity of gastrointestinal tracts | |
| Shaw | The Use of GnRH Analogues to Control Menstrual Bleeding | |
| HK40012837B (en) | Methods of treating uterine fibroids and endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |